Meningococcal group A, C, Y and W-135 conjugate vaccine
- 1 June 2010
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 9 (6), 429-430
- https://doi.org/10.1038/nrd3194
Abstract
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11-55 years.Keywords
This publication has 12 references indexed in Scilit:
- Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccinesVaccine, 2010
- Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal DiseaseClinical Infectious Diseases, 2010
- Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all agesVaccine, 2009
- Global epidemiology of meningococcal diseaseVaccine, 2009
- Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in AfricaVaccine, 2009
- Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in InfantsJAMA, 2008
- A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infantsVaccine, 2007
- A universal vaccine for serogroup B meningococcusProceedings of the National Academy of Sciences of the United States of America, 2006
- Prospects for Vaccine Prevention of Meningococcal InfectionClinical Microbiology Reviews, 2006
- Vaccine Potential of theNeisseria meningitidis2086 LipoproteinInfection and Immunity, 2004